Host background immunity and human immunodeficiency virus protective vaccines, a major consideration for vaccine efficacy in Africa and in developing countries
Borkow, G.; Bentwich, Z.
Clinical and Diagnostic Laboratory Immunology 9(3): 505-507
2002
ISSN/ISBN: 1071-412X PMID: 11986252 DOI: 10.1128/cdli.9.3.505-507.2002Document Number: 252081
Document emailed within 0-6 h
Related Documents
Steele, A.D.; Madhi, S.A.; Louw, C.E.; Bos, P.; Tumbo, J.M.; Werner, C.M.; Bicer, C.; De Vos, B.; Delem, A.; Han, H.H. 2011: Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South Africa Pediatric Infectious Disease Journal 30(2): 125-130Kreiss, J.K.; Castro, K.G. 1990: Special considerations for managing suspected human immunodeficiency virus infection and AIDS in patients from developing countries Journal of Infectious Diseases 162(4): 955-960
Jadhav, S.; Gautam, M.; Gairola, S. 2014: Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices Clinical Microbiology and Infection: the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 20(Suppl 5): 37-44
Abdurrahman, M.B.; Taqi, A.M. 1981: Measles immunity and immunization in developing countries of Africa: a review African Journal of Medicine and Medical Sciences 10(1-2): 57-62
Heller, T.; Wallrauch, C.; Lessells, R.J.; Goblirsch, S.; Brunetti, E. 2010: Short course for focused assessment with sonography for human immunodeficiency virus/tuberculosis: preliminary results in a rural setting in South Africa with high prevalence of human immunodeficiency virus and tuberculosis American Journal of Tropical Medicine and Hygiene 82(3): 512-515
Kline, M.W.; Lewis, D.E.; Hollinger, F.B.; Reuben, J.M.; Hanson, L.C.; Kozinetz, C.A.; Dimitrov, D.H.; Rosenblatt, H.M.; Shearer, W.T. 1994: A comparative study of human immunodeficiency virus culture, polymerase chain reaction and anti-human immunodeficiency virus immunoglobulin A antibody detection in the diagnosis during early infancy of vertically acquired human immunodeficiency virus infection Pediatric Infectious Disease Journal 13(2): 90-94
Koyanagi, A.; Humphrey, J.H.; Ntozini, R.; Nathoo, K.; Moulton, L.H.; Iliff, P.; Mutasa, K.; Ruff, A.; Ward, B.; Chidawanyika, H.; Hargrove, J.; Mahomva, A.I.; Majo, F.; Malaba, L.C.; Mbizvo, M.T.; Mzengeza, F.; Ndhlovu, M.; Piwoz, E.; Propper, L.; Rambanepasi, P.; Ruff, A.J.; Tavengwa, N.; Zijenah, L.S.; Zunguza, C.D.; Zvandasara, P. 2011: Morbidity among human immunodeficiency virus-exposed but uninfected, human immunodeficiency virus-infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy Pediatric Infectious Disease Journal 30(1): 45-51
Kitamura, T. 1987: Trends in research in developing new type of vaccines--aiming at efficacy and safety. Present status of the development of AIDS vaccine Nihon Rinsho. Japanese Journal of Clinical Medicine 45(10): 2444-2447
Dane, D.S.; Dick, G.W.A.; Connolly, J.H.; Fisher, O.D.; McKeown, F.; Briggs, M.; Nelson, R.; Wilson, D. 1957: Vaccination Against Poliomyelitis with Live Virus Vaccines: 1. a Trial of TN Type Ii Vaccine. 2. a Trial of SM Type i Attenuated Poliomyelitis Virus Vaccine. 3. the Evaluation of TN and SM Virus Vaccines BMJ 1(5010): 59-74
Felman, Y.M. 1990: Recent developments in sexually transmitted diseases: is heterosexual transmission of human immunodeficiency virus a major epidemiologic factor in the spread of acquired immunodeficiency syndrome? II: The United States and western Europe Cutis 46(2): 114 116-7
Nakalembe, M.; Mirembe, F.M.; Banura, C. 2015: Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy Infectious Agents and Cancer 10: 17
Nicolosi, A. 1992: Human immunodeficiency virus (HIV-1): infectivity transmission, risk behaviours and host susceptibility Functional Neurology 7(1): 13-29
Le Pont, F.ço.; Hatungimana, V.; Guiguet, M.; Ndayiragije, A.; Ndoricimpa, J.; Niyongabo, T.; Larouzé, B. 2003: Assessment of occupational exposure to human immunodeficiency virus and hepatitis C virus in a referral hospital in Burundi, Central Africa Infection Control and Hospital Epidemiology 24(10): 717-718
Dhalla, S. 2015: An update on human immunodeficiency virus vaccine preparedness studies Journal of Medical Microbiology 64(7): 731-738
Camafort, M.; Bronsoms, J.; Vallés, M.; Pocar, C.; García-Bragado, F. 1999: Invasive aspergillosis in a patient with human immunodeficiency virus infection (HIV) and relatively preserved immunity Anales de Medicina Interna 16(9): 489-490
Mohamoud, Y.A.; Miller, F.D.; Abu-Raddad, L.J. 2014: Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker World Journal of Gastroenterology 20(36): 12734-12752
Bearden, D.; Steenhoff, A.P.; Dlugos, D.J.; Kolson, D.; Mehta, P.; Kessler, S.; Lowenthal, E.; Monokwane, B.; Anabwani, G.; Bisson, G.P. 2015: Early antiretroviral therapy is protective against epilepsy in children with human immunodeficiency virus infection in botswana Journal of Acquired Immune Deficiency Syndromes 69(2): 193-199
Kania, D.; Sangaré, L.; Sakandé, J.; Koanda, A.; Nébié, Y.K.; Zerbo, O.; Combasséré, A.W.; Guissou, I.P.; Rouet, F.ço. 2009: A new strategy to improve the cost-effectiveness of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and syphilis testing of blood donations in sub-Saharan Africa: a pilot study in Burkina Faso Transfusion 49(10): 2237-2240
Amoroso, P.; Izzo, C.; Smeraglia, R.; Lettieri, G.; Maio, G.; Flaminio, G.; Giorgio, A.; Fico, P.; Pierri, P.; Tarro, G. 1987: Absence of risk of human immunodeficiency virus (HIV) infection in recipients of hepatitis B vaccine European Journal of Epidemiology 3(3): 323-324
Habel, A.; Chanel, C.; Le Grand, R.; Martinon, F.; Couillin, L.; Moog, C.; Doms, R.; Gauduin, M.C.; Hurtrel, B.; Guillet, J.G.; Aubertin, A.M.; Girard, M. 2000: DNA vaccine protection against challenge with simian/human immunodeficiency virus 89.6 in rhesus macaques Developments in Biologicals 104: 101-105